respiratori
virus
frequent
caus
symptomat
infect
children
often
detect
also
healthi
children
investig
myxoviru
resist
protein
mxa
viperin
tripartitemotif
messeng
rna
index
nasal
swab
potenti
biomark
viral
respiratori
infect
children
respiratori
virus
detect
polymeras
chain
reaction
swab
nasal
mxa
viperin
index
increas
symptomat
virusposit
children
nasal
viperin
index
found
robust
marker
viral
respiratori
tract
infect
sensit
specif
distinguish
children
symptomat
viru
infect
asymptomat
virusneg
children
respiratori
virus
frequent
caus
symptomat
infect
children
often
detect
also
healthi
children
investig
myxoviru
resist
protein
mxa
viperin
tripartitemotif
messeng
rna
index
nasal
swab
potenti
biomark
viral
respiratori
infect
children
respiratori
virus
detect
polymeras
chain
reaction
swab
nasal
mxa
viperin
index
increas
symptomat
virusposit
children
nasal
viperin
index
found
robust
marker
viral
respiratori
tract
infect
sensit
specif
distinguish
children
symptomat
viru
infect
asymptomat
virusneg
children
keyword
biomark
myxoviru
resist
protein
respiratori
virus
tripartitemotif
viperin
multiplex
polymeras
chain
reaction
pcr
method
increasingli
use
respiratori
viru
detect
howev
result
may
difficult
interpret
rhinovirus
coronavirus
respiratori
virus
also
frequent
detect
asymptomat
children
specif
host
respons
biomark
viral
infect
need
transcript
numer
antivir
protein
induc
interferon
viral
infect
myxoviru
resist
protein
mxa
viperin
also
known
tripartitemotif
among
interferonregul
protein
blood
mxa
level
report
specif
marker
viral
infect
viperin
gene
express
induc
rhinoviru
virus
evalu
mxa
viperin
messeng
rna
mrna
candid
biomark
symptomat
viral
respiratori
tract
infect
rti
children
biomark
measur
nasal
swab
specimen
use
detect
virus
studi
part
prospect
birthcohort
studi
step
healthi
develop
wellb
children
step
children
recruit
studi
follow
rti
first
year
life
parentfil
symptom
diari
visit
studi
clinic
occurr
symptom
rti
schedul
appoint
set
coincid
subject
age
month
studi
personnel
document
symptom
sign
use
structur
form
obtain
nasal
swab
specimen
use
flock
nylon
swab
copan
sampl
studi
collect
februari
june
vaccin
inform
collect
electron
registri
wellbabi
clinic
ethic
committe
hospit
district
southwest
finland
approv
studi
parent
gave
written
inform
consent
nasal
swab
suspend
phosphatebuff
salin
nucleic
acid
extract
nuclisens
easymag
magnapur
roch
instrument
revers
transcript
realtim
pcr
rhinoviru
enteroviru
respiratori
syncyti
viru
rsv
done
use
lock
nucleic
acid
describ
previous
seeplex
multiplex
pcr
assay
seegen
perform
accord
manufactur
instruct
adenoviru
coronavirus
human
metapneumoviru
rhinoviru
influenza
b
virus
parainfluenza
viru
type
rsva
rsvb
rhinoviru
rsv
posit
result
either
one
test
consid
posit
test
result
human
bocaviru
detect
separ
pcr
test
done
previous
describ
nasal
swab
nucleic
acid
first
examin
mxa
mrna
viperin
mrna
relat
mxa
viperin
mrna
cell
densiti
use
mrna
surrog
measur
cell
sampl
quantit
mrna
first
done
along
mxa
mrna
subsequ
along
viperin
mrna
measur
express
index
calcul
divid
mxa
viperin
mrna
copi
number
actin
mrna
copi
number
per
sampl
sampl
mrna
copi
number
measur
exclud
analysi
multipl
comparison
made
use
kruskalw
test
pairwis
comparison
mannwhitney
u
test
receiv
oper
characterist
roc
analys
conduct
evalu
capabl
nasal
express
index
distinguish
symptomat
viral
infect
asymptomat
virusneg
case
wilson
score
interv
use
calcul
confid
interv
ci
sensit
specif
p
valu
consid
signific
statist
analys
perform
use
ibm
spss
statist
version
obtain
nasal
swab
specimen
children
eight
case
exclud
copi
number
per
sampl
measur
result
total
case
children
vaccin
histori
avail
vaccin
day
sampl
live
attenu
viru
vaccin
administ
children
receiv
oral
rotaviru
vaccin
receiv
measl
mump
rubella
mmr
vaccin
asymptomat
virusneg
children
particular
interest
regard
vaccin
group
children
receiv
oral
rotaviru
vaccin
mmr
vaccin
inactiv
vaccin
day
nasal
sampl
figur
inactiv
vaccin
effect
mxa
roc
analysi
done
separ
case
vaccin
live
viru
vaccin
day
prior
mxa
sampl
compar
symptomat
virusposit
asymptomat
virusneg
children
supplementari
figur
area
roc
curv
auc
ci
ci
respect
mxa
index
cutoff
level
determin
largest
sum
sensit
specif
roc
analysi
case
without
recent
live
vaccin
cutoff
yield
sensit
ci
specif
ci
distinguish
symptomat
virusposit
children
asymptomat
virusneg
children
case
includ
sensit
ci
specif
ci
children
recent
live
viru
vaccin
exclud
mxa
index
cutoff
level
asymptomat
virusposit
children
includ
children
without
recent
live
vaccin
administr
supplementari
tabl
viperin
index
measur
sampl
increas
viperin
index
found
children
detect
respiratori
virus
supplementari
tabl
nasal
viperin
index
high
symptomat
virusposit
children
median
iqr
tabl
vaccin
affect
viperin
express
supplementari
figur
roc
analysi
auc
ci
viperin
index
differenti
symptomat
virusposit
asymptomat
virusneg
children
supplementari
figur
roc
analysisderiv
cutoff
valu
provid
sensit
ci
specif
ci
nasal
index
determin
sampl
index
significantli
differ
group
figur
median
index
iqr
symptomat
virusposit
children
iqr
asymptomat
virusneg
children
p
vaccin
affect
express
supplementari
figur
symptomat
virusposit
asymptomat
virusneg
children
supplementari
figur
found
nasal
mxa
viperin
express
increas
children
symptomat
viral
respiratori
infect
biomark
mrna
measur
respiratori
viru
detect
perform
pcr
nasal
swab
blood
mxa
concentr
report
promis
biomark
viral
infect
earlier
report
blood
mxa
level
children
accord
symptom
viru
detect
similar
studi
line
current
studi
blood
mxa
level
found
increas
symptomat
virusposit
subject
studi
done
nakabayashi
et
al
blood
mxa
level
higher
children
viral
infect
compar
bacteri
infect
forster
et
al
report
increas
mxa
protein
level
nasopharyng
swab
children
rti
use
enzymelink
immunosorb
assay
knowledg
first
studi
nasal
mxa
mrna
express
data
nasal
mxa
index
elev
also
asymptomat
virusposit
children
limit
use
biomark
indic
viru
caus
ill
viperin
potent
antivir
protein
gene
express
document
increas
blood
nasal
epithelium
respiratori
viral
infect
support
previou
studi
found
viperin
express
nasal
sampl
markedli
increas
virusposit
rti
viperin
mrna
copi
number
close
zero
asymptomat
virusneg
children
asymptomat
virusposit
children
except
case
thu
viperin
seem
perform
better
mxa
marker
symptomat
viral
rti
howev
viperin
report
induc
also
bacteri
lipopolysaccharid
potenti
viperin
differenti
viral
bacteri
infect
remain
clarifi
studi
index
abl
distinguish
children
rti
healthi
children
find
support
notion
ubiquit
express
somewhat
independ
viru
activ
innat
immun
receptor
benefit
nasal
mrna
measur
biomark
compar
blood
protein
level
determin
includ
lack
need
blood
sampl
possibl
simultan
autom
analysi
parallel
viru
pcr
possibl
disadvantag
method
gene
express
probabl
vari
rapidli
ill
compar
rel
steadi
blood
protein
level
furthermor
although
actin
mrna
use
marker
cellular
quantiti
sampl
quantit
analysi
difficult
nasal
swab
sampl
blood
effect
vaccin
import
consider
develop
infect
biomark
children
studi
live
attenu
rotaviru
vaccin
administr
associ
increas
nasal
mxa
index
similar
effect
live
vaccin
blood
mxa
found
earlier
studi
studi
done
yellow
fever
vaccin
found
correl
recent
vaccin
viperin
express
pcr
test
respiratori
virus
limit
potenti
virus
test
strength
virolog
methodolog
use
separ
pcr
rhinoviru
enterovirus
rsv
addit
multiplex
pcr
low
number
asymptomat
virusposit
case
fact
fecal
sampl
test
enter
virus
limit
studi
mean
age
children
without
rti
rather
close
earlier
report
higher
baselin
level
blood
mxa
children
compar
adult
similar
level
age
month
conclud
studi
suggest
nasal
mxa
viperin
mrna
index
potenti
biomark
viral
rti
children
particular
viperin
mrna
index
found
robust
biomark
respiratori
viru
caus
symptom
biomark
analyz
pcr
togeth
virus
nasal
swab
sampl
studi
need
establish
possibl
role
nasal
mxa
viperin
index
guid
clinic
decis
make
supplementari
materi
avail
journal
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
